A phase III trial of adjuvant ribociclib plus endocrine therapy vs endocrine therapy alone in patients with HR+/HER2- early breast cancer: final invasive disease-free survival results from the NATALEE trial
- Author(s)
- Hortobagyi, GN; Lacko, A; Sohn, J; Cruz, F; Borrego, MR; Manikhas, A; Park, YH; Stroyakovskiy, D; Yardley, DA; Huang, CS; Fasching, PA; Crown, J; Bardia, A; Chia, S; Im, SA; Martin, M; Loi, S; Xu, B; Hurvitz, S; Barrios, C; Untch, M; Moroose, R; Visco, F; Parnizari, F; Zarate, JP; Li, Z; Waters, S; Chakravartty, A; Slamon, D;
- Journal Title
- Annals of Oncology
- Publication Type
- Online publication before print
- Abstract
- BACKGROUND: NATALEE assessed efficacy and tolerability of 3 years of adjuvant ribociclib plus NSAI compared with a nonsteroidal aromatase inhibitor (NSAI) alone in a broad population of patients with HR+/HER2- early breast cancer, including a select group without nodal involvement. This is the final preplanned analysis of invasive disease-free survival (iDFS). PATIENTS AND METHODS: Premenopausal/postmenopausal women and men were randomized 1:1 to ribociclib (n=2549; 400 mg/day, 3 weeks on/1 week off for 36 months) plus NSAI (letrozole 2.5 mg/day or anastrozole 1 mg/day for 60 months) or NSAI alone (n=2552). Men and premenopausal women also received goserelin (3.6 mg once every 28 days). Patients had anatomical stage IIA (N0 with additional risk factors or N1), IIB, or III disease. The primary endpoint was iDFS. Secondary efficacy endpoints were recurrence-free survival (RFS), distant DFS (DDFS), and overall survival (OS). This final iDFS analysis was planned after ≈500 events. RESULTS: At data cutoff (21 July 2023), ribociclib was stopped for 1996 patients (78.3%); 1091 (42.8%) completed 3 years of ribociclib, and ribociclib treatment was ongoing for 528 (20.7%). Median follow-up for iDFS was 33.3 months. Overall, 226 and 283 iDFS events occurred with ribociclib plus NSAI vs NSAI alone, respectively. Ribociclib plus NSAI demonstrated significant iDFS benefit over NSAI alone (Hazard Ratio 0.749, 95% Confidence Interval [CI] 0.628-0.892; P=0.0012). The 3-year iDFS rates were 90.7% (95% CI 89.3%-91.8%) vs 87.6% (95% CI 86.1%-88.9%). A consistent benefit was observed across prespecified subgroups, including stage (II/III) and nodal status (+/-). DDFS and RFS favored ribociclib plus NSAI. OS data were immature. No new safety signals were observed. CONCLUSIONS: With longer follow-up and most patients off ribociclib, NATALEE continues to demonstrate iDFS benefit with ribociclib plus NSAI over NSAI alone in the overall population and across key subgroups. Observed adverse events remained stable.
- Keywords
- Natalee; breast cancer; cyclin-dependent kinase 4 and 6 inhibitors; hormone-receptor positive; human epidermal growth factor receptor 2 negative; ribociclib
- Department(s)
- Medical Oncology
- Publisher's Version
- https://doi.org/10.1016/j.annonc.2024.10.015
- Open Access at Publisher's Site
https://doi.org/10.1016/j.annonc.2024.10.015- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2024-11-28 05:45:58
Last Modified: 2024-11-28 06:29:14